Contact Jacoby & Meyers
Dangerous Drug Lawyers
Call us Today 800-977-5614

Rituxan is a cancer medication that works to prevent the growth and spread of cancer cells in the body. This drug has also been prescribed to treat arthritis and certain rare disorders that cause inflammation of blood cells and other tissues. Rituxan also became popular in treating Lupus, although this use is not approved by the FDA. It is classified as an immunosuppressant. In 2007, drug sales totaled $2.3 billion for Rituxan.
In 2006, the FDA announced that it had reports of patients who died after being prescribed Rituxan to treat Lupus. These patients suffered from Progressive Multifocal Leukencephalopathy (PML). PML is a rare and potentially fatal viral disease that shows itself through the inflammation of white matter in the brain. It can be seen most often in people already suffering from immune deficiency, such as transplant patients or people with AIDS. In a few cases, PML was found even a year after the last dose of Rituxan was administered. Of the 57 cases of PML that were reported to the FDA, 90 percent proved fatal.
Also, the FDA found links to brain infection in patients being treated for arthritis and lymphoma.
Serious side effect may include:
Less serious Rituxan side effects may include:
Lawyer Advertising. This website is designed for general information only, and in no way is intended to constitute legal advice nor the formation of a lawyer/client relationship without a signed, written agreement. Testimonials or endorsements do not constitute a guarantee, warranty, or prediction regarding the outcome of your legal matter. You pay no fees or costs unless we recover for you. This website contains dramatizations. Prior results are not a guarantee of a future outcome. Jacoby & Meyers does not accept all cases and works cooperatively with co-counsel and/or other law firms with whom it has joint agreements who might potentially handle your cases. We look forward to helping you with your claim.
© 2012-2025 Jacoby & Meyers. All rights reserved.